I know that PET-CT has been mentioned many times in this forum as valuable for assessment of disease evolution and spread to other organs. I have been rather enthusiastic about it myself, but it appears that (at least) in the particular case of prostate cancer, its usefulness is still subject of scientific debate. That is, there are reports of false positives/negatives in trials using PET and also the best type of radioactive tracer that is used to identify the metabolic activity of certain cancer cells seems questionable. As far as I understand, FDG is the most widespread tracer in use today, while studies have shown that others such as choline or acetate are more accurate in the case of prostate cancer.
My question this time is: in PET-CT units open to public are the patients injected with a radioactive tracer that is specifically targeted to the type of cancer they suffer of, or it is just FDG for everyone? Would it even be possible to try several tracers for best accuracy?
I do not wish to spoil anyone's joy about this wonderful method that is available to keep track of cancer cells, but it is peharps good to be realistic about its true capability in particular cases... and ask the right questions before and after such tests.
Thank you and I look forward to your replies.